Tumor associated nucleic acids and uses therefor

Details Tumor associated nucleic acids and uses therefor Tumor associated nucleic acids and uses therefor

2005-09-30

2008-08-12

Harris, Alana M. (Department: 1643)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

C436S064000, C436S086000, C514S001000, C514S002600, C514S004300, C424S009100, C424S009200, C424S009321, C424S009322, C424S009340

Reexamination Certificate

active

07411042

ABSTRACT:
The invention describes SAGE (sdph3.10) and sdp3.5 tumor associated nucleic acids, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such nucleic acid molecules, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a sdph3.10 and/or sdp3.5 gene product.

REFERENCES:
patent: 5342774 (1994-08-01), Boon et al.
patent: 5405940 (1995-04-01), Boon et al.
patent: 5464745 (1995-11-01), Mierendorf et al.
patent: 5487974 (1996-01-01), Boon-Falleur et al.
patent: 5571711 (1996-11-01), van der Bruggen et al.
patent: 5587289 (1996-12-01), Lurquin et al.
patent: 5589334 (1996-12-01), Coulie et al.
patent: 5610013 (1997-03-01), Van den Eynde et al.
patent: 5620886 (1997-04-01), Brichard et al.
patent: 5629166 (1997-05-01), van der Bruggen et al.
patent: 5677430 (1997-10-01), Goodwin et al.
patent: 5880102 (1999-03-01), George et al.
patent: PCT/US92/04354 (1992-11-01), None
patent: PCT/US95/12117 (1996-04-01), None
Traversari et al., J. Exp. Med. 176:1453-1457, 1992.
van der Bruggen et al., Science 254:1643, 1991.
De Plaen et al., Immunogenetics 40:360-369, 1994.
Van den Eynde & Brichard, Curr. Opin. Immunol. 7:674-681, 1995.
Coulie et al., Stem Cells 13:393-403, 1995.
Van den Eynde & van der Bruggen, Curr. Opin. Immunol. 9:684-693, 1997.
Topalian et al., J. Exp. Med. 183:1965-1971, 1996.
Thomson et al., Proc. Natl. Acad. Sci. USA 92:5845-5849, 1995.
Gilbert et al., Nature Biotechnol. 15:1280-1284, 1997.
Thomson et al., J. Immunol. 157(2):822-826, 1996.
Tam et al., J Exp. Med. 171(1):299-306, 1990.
Allsopp et al., Eur, J. Immunol. 26(8):1951-1959, 1996.
Ulmer et al., Science 259:1745-1748, 1993.
Altman et al., Science 274:94-96, 1996.
Dunbar et al., Curr. Biol. 8:413-416, 1998.
Hubank & Schatz, Nucl. Acids Res. 22:5640, 1994.
Brichard et al., Eur, J. Immunol. 26:224-230, 1996.
van der Bruggen et al., Eur. J. Immunol. 24:3038-3043, 1994.
Herman et al., Immunogenetics 43:377-383, 1996.
Parker et al., J. Immunol. 152:163-175, 1994.
Rammensee et al., Immunogenetics 41:178-228, 1995.
Parker et al., J. Immunol. 149:3580-3587, 1992.
Printout from Database Search of Public Nucleic Acid Sequence database using BLAST Algorithm, Oct. 23, 1998.
Hillier et al., Database EMBL, HS1291592, Acc. No. AA496651, Jul. 3, 1997.
Marra et al., Database EMBL, Acc. No. MMAA70068, Jan. 2, 1977.
Strausberg, Database EMBL, HSAA25285, Acc. No. AA213817, Feb. 3, 1997.
Strausberg, Database EMBL, ID/Acc No. AA807217, Feb. 16, 1998.
Strausberg, Database EMBL, Acc. No. AI052728, Jul. 13, 1998.
Adams et al., Database EMBL, ID/Acc. No. AQ280053, Nov. 23, 1998.
Strausberg, Database EMBL, ID/Acc. No. AA883800, Mar. 30, 1998.
Strausberg, Database EMBL, ID/Acc. No. AA948168, May 5, 1998.
Strausberg, Database EMBL, ID/Acc. No. AI378017, Jan. 28, 1999.
Gupta et al., Cancer Letters, 69(3): 173-180 (1993).
Tuting et al., Eur J of Immunol, 27(10):2702-2707 (1997).
Song et al., Anticancer Research, 16(3a): 1171-1175 (1996).
Nucleic Acid Database, Accession #AA213817, 1997.
Rees et al., Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. Biotechniques. Jan. 1996;20(1):102-4, 106, 108-10.
Nucleic Acid Database, Accession #U89672, 1997.
Rojanasakul, Y. Antisense oligonucleotide therapeutics: drug delivery and targeting. Advanced Drug Delivery Reviews 18: 115-131, 1996.
Nucleic Acid Database, Accession #W86797, 1996.
Mullins and Mullins. Perspective Series: Molecular medicine in genetically engineered animals. J Clin Invest 98(11): S37-S40, 1996.
Taurog et al., HLA-B27 in inbred and non-inbred transgenic mice. J. of Immunology 141(11):4020-4023, 1988.
Hammer et al., Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2 microglobulin: an animal model of HLA-B27-associated human disorders. Cell 63: 1099-1112, 1990.
Mullins et al., Fulminant hypertension in transgenic rats harbouring the mouse ren-2 gen. Nature 344: 541-544, 1990.
Mullins and Mullins. Transgenesis in nonmurine species. Hypertension 22: 630-633, 1993.
Kappel et al., Regulating gene expression in transgenic animals. Current Opinion in Biotechnology 3:548-553, 1992.
Houdebine. Production of pharmaceutical proteins from transgenic animals. J of Biotechnology 34: 269-287, 1994.
Wall. Transgenic livestock: progress and prospects for the future. Theriogenology 45: 57-68, 1996.
Overbeek. Transgene expression: effects of integration site and copy number within Transgenic animal technology. A laboratory handbook, 1994.
Stratagene catalog p. 118 and accompanying instruction manual, 1997.

Affiliated with

Also associated with

Rating

Tumor associated nucleic acids and uses therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumor associated nucleic acids and uses therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor associated nucleic acids and uses therefor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3998019